BD Connecta Stopcock Without Extension Tube Catalog No. 394600 (OUS)

FDA Device Recall #Z-1432-2022 — Class II — May 9, 2022

Recall Summary

Recall Number Z-1432-2022
Classification Class II — Moderate risk
Date Initiated May 9, 2022
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Becton Dickinson & Company
Location Franklin Lakes, NJ
Product Type Devices
Quantity 2800270

Product Description

BD Connecta Stopcock Without Extension Tube Catalog No. 394600 (OUS)

Reason for Recall

May have the potential for leakage at the housing component of the stopcock, may result in delay or interruption in treatment, exposure to infusate and biohazardous material, under dosing/under infusion, contamination and/or air ingress.

Distribution Pattern

Worldwide distribution - US Nationwide distribution in the states of AK, AR, AZ, CA, CO, FL, GA, IL, IN, KS, MA, MD, MI, MN, MO, MS, NC, NE, NJ, NV, NY, OH, OR, PA, SD, TN, TX, UT, VA, WA, WV and the countries of Belgium, China, India, Indonesia, Japan, Korea, Nepal, Philippines, Singapore, Sri Lanka, Thailand, Vietnam.

Lot / Code Information

GTIN: 382903946006 Lot Numbers/Exp. Date: 1126369 4/30/2024 1126368 4/30/2024 1152277 5/31/2024 1126371 4/30/2024 1152275 5/31/2024 1126366 4/30/2024 1124513 4/30/2024 1126361 4/30/2024 1214381 7/31/2024 1123653 4/30/2024 1123644 4/30/2024 1098342 3/31/2024 1098335 3/31/2024 1098339 3/31/2024 1085949 2/29/2024 1098333 3/31/2024 1090036 2/29/2024 1085634 2/29/2024 1085635 2/29/2024 1090038 2/29/2024 1090820 2/29/2024 1083414 2/29/2024 1063420 2/29/2024 1063419 2/29/2024 1063417 2/29/2024 1060787 2/29/2024 1060784 2/29/2024 1033322 1/30/2024 1060783 2/29/2024 1060791 2/29/2024

Other Recalls from Becton Dickinson & Company

Recall # Classification Product Date
Z-1496-2026 Class II 10mL Non-Sterile BD Luer-Lok Tip Syringe Only. ... Jan 27, 2026
Z-0504-2026 Class II BD Luer Tip Caps; Catalog Number(s) or Model N... Oct 14, 2025
Z-0736-2024 Class II PosiFlush Prefilled Saline Syringe with General... Nov 16, 2023
Z-0349-2024 Class II BD Alaris Pump infusion sets (Product Name, Cat... Oct 11, 2023
Z-0351-2024 Class II BD Extension Sets (Product Name, Catalog #) ... Oct 11, 2023

Frequently Asked Questions

Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately — you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.